Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 08 Aug 2016 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.
- 08 Aug 2016 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.
- 08 Aug 2016 This trial was completed in Ireland and Spain, according to the European Clinical Trials Database.